← All Sponsors

SPONSOR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Total Trials

23

Recruiting

23

Phases

Phase 2, EARLY_Phase 1, Phase 1, Phase 2, Phase 2, Phase 3, Phase 3

Conditions studied: Prostate Cancer (Post Prostatectomy)Bladder Cancer Gastric Adenocarcinoma Gastro-esophageal Junction Adenocarcinoma Pancreatic Adenocarcinoma Small Cell Lung Cancer Safety Issues Limited Stage Small Cell Lung Cancer Hepatocellular Carcinoma Radiotherapy

Adaptive Radiotherapy for Genitourinary Cancers

Prostate Cancer (Post Prostatectomy)

NCT06808971 Phase 2

Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ

Gastric Adenocarcinoma

NCT06789679 Phase 2

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma

A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer

Small Cell Lung Cancer

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

NCT05443646 Phase 2

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Limited Stage Small Cell Lung Cancer

NCT07034742 EARLY_Phase 1

Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer

Gastric Adenocarcinoma

NCT06389422 Phase 2

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Hepatocellular Carcinoma

Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy

Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma

Siewert Type II Adenocarcinoma of Esophagogastric Junction

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

NCT06087068 Phase 2

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

NCT06202001 Phase 1, Phase 2

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Metastatic Colorectal Cancer

NCT05749302 Phase 2, Phase 3

Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins

NCT06411457 Phase 2

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Breast Cancer, Familial Male

Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases

Colorectal Liver Metastasis (CRLM)

NCT06958627 Phase 2, Phase 3

The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

HER2 Positive Breast Cancer

NCT07014202 Phase 2

Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy

Non-Small Cell Lung Cancer

MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy

Esophagus Cancer

NCT07443397 Phase 3

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

Whole-Brain Radiotherapy

NCT06793813 Phase 2

Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)

Stage IVB Lung Cancer

NCT07383246 Phase 3

CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC

Medullary Thyroid Carcinoma